---
schema_version: "secwatch.filing_event.v1"
accession: "0001551152-25-000043"
form_type: "8-K"
ticker: "ABBV"
cik: "0001551152"
company_name: "AbbVie Inc."
filed_at: "2025-10-03T23:59:59+00:00"
generated_at: "2026-05-17T04:44:48.023754+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# AbbVie cuts FY 2025 adjusted EPS guidance to $10.38-$10.58 on $2.68B Q3 IPR&D charge

## Summary
- Q3 2025 acquired IPR&D and milestones expense of $2.68B reduces adjusted EPS by $1.50.
- Q3 2025 adjusted EPS guidance revised to $1.74-$1.78 from prior $3.24-$3.28.
- Full-year 2025 adjusted EPS guidance lowered to $10.38-$10.58 from $11.88-$12.08.
- Previously announced FY guidance excluded Q3 IPR&D; further IPR&D beyond Q3 not forecasted.
- Q3 results not finalized; preliminary estimates subject to closing procedures.

## SEC filing metadata
- accession: 0001551152-25-000043
- form_type: 8-K
- ticker: ABBV
- cik: 0001551152
- company_name: AbbVie Inc.
- filed_at: 2025-10-03T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000043/0001551152-25-000043-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1551152/000155115225000043/abbv-20251003.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001551152-25-000043
- JSON: https://secwatch.observer/filing/0001551152-25-000043.json
- Plain text: https://secwatch.observer/filing/0001551152-25-000043.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.